A Phase I Study to Assess Ebola Vaccines cAd3-EBO Z and MVA-EBO Z

计划入组 38 人 · 首次发布于 2015 年 5 月 22 日

202091 (EBOLA Z CHAD3-005)

计划入组 3,000 人

202090 (EBOLA Z CHAD3-004)

计划入组 600 人

Z-338 Z-338

Z-11410

Z-1054

E-Z-EM, Inc.

United States

Alam, Dr Z Yasim

Canada

BIOVICO SP Z O O

Poland

FDA Grants Priority Review to Intellia's Lonvo-z, an In Vivo CRISPR Therapy for Hereditary Angioedema

Intellia's CRISPR Gene Therapy Shows 98% Reduction in HAE Attacks After Three Years

Intellia's CRISPR Gene Therapy Achieves 87% Reduction in Hereditary Angioedema Attacks in Phase 3 Trial